Mucinous Adenocarcinoma Predicts Poor Response and Prognosis in Patients With Locally Advanced Rectal Cancer: A Pooled Analysis of Individual Participant Data From 3 Prospective Studies
Jianwei Zhang,Xiaoyu Xie,Zehua Wu,Huabin Hu,Yue Cai,Jianxia Li,Jiayu Ling,Miaomiao Ding,Weiwei Li,Yanhong Deng
DOI: https://doi.org/10.1016/j.clcc.2021.06.004
IF: 4.035
2021-12-01
Clinical Colorectal Cancer
Abstract:<h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Purpose</h3><p>To evaluate the predictive implications and prognosis of mucinous adenocarcinoma (MAC) in locally advanced rectal cancer (LARC) with intensified neoadjuvant treatment.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Methods</h3><p>Individual patient data of LARC patients from 3 prospective clinical trials was analyzed. Neoadjuvant treatment regimens comprised chemoradiotherapy (CRT) with fluorouracil (5-FU) or mFOLFOX6, neoadjuvant chemotherapy alone with mFOLFOX6 or mFOLFOXIRI. The postoperative pathological result, local recurrence and disease-free survival (DFS) were retrospectively analyzed in patients with MAC and adenocarcinoma (AC) with neoadjuvant treatment.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Results</h3><p>Totally, 743 patients were recruited, with 620 patients eligible for analysis. Fifty-three (8.5%) patients were MAC. The pathological complete response (pCR) rate and tumor downstaging rate (ypStage 0-I) between MAC and AC patients was 7.5% <em>vs.</em> 22.0% (<em>P</em> = 0.01) and 20.8% <em>vs.</em> 48.7% (<em>P</em> < 0.001), respectively. Among patients receiving preoperative CRT with 5FU or mFOLFOX6, the pCR rate and tumor downstaging rate between MAC and AC patients was 11.1% <em>vs.</em> 27.3% (<em>P</em>=0.03) and 23.7% <em>vs.</em> 52.6% (<em>P</em>=0.001), respectively. Regarding neoadjuvant chemotherapy alone with mFOLFOX6 or mFOLFOXIRI, the pCR rate and tumor downstaging rate was 0 <em>vs.</em>13.2% (<em>P</em>=0.11) and 11.8% <em>vs.</em> 42.5% (<em>P</em>=0.03) between MAC and AC group, respectively. With the median follow-up time of 38.9 months, the 3-year DFS and 3-year locoregional recurrence rate was 58.4% <em>vs.</em> 77.6% (<em>P</em>=0.02) and 26.0% <em>vs.</em> 5.7% (<em>P</em>=0.001) in the MAC and AC group, respectively. MAC (HR 1.85, 95% CI, 1.15-2.98), PNI (HR 3.23, 95% CI, 1.85-5.72) and LVI (HR 2.04, 95% CI, 1.02-4.08) were independent prognosis factors and were associated with worse DFS.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Conclusions</h3><p>Patients with MAC of the rectum are associated with a lower pCR rate and tumor downstaging rate, higher incidence of local recurrence and poorer DFS with neoadjuvant treatment.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Minor </h3><p>The predictive implication and prognosis of Mucinous adenocarcinoma (MAC) in locally advanced rectal cancer (LARC) with intensified neoadjuvant treatment strategies from 3 prospective clinical trials had been explored. The pathological complete response (pCR) rate and tumor downstaging rate (ypStage 0-I) between MAC and adenocarcinoma (AC) patients was 7.5% <em>vs.</em> 22.0% (<em>P</em> = 0.01) and 20.8% <em>vs.</em> 48.7% (<em>P</em> < 0.001), respectively. The 3-year disease-free survival (DFS) and 3-year locoregional recurrence rate was 58.4% <em>vs.</em> 77.6% (<em>P</em>=0.02) and 26.0% <em>vs.</em> 5.7% (<em>P</em>=0.001) in the MAC and AC group, respectively. MAC was a poor prognostic factor in LARC with neoadjuvant treatment.</p>
oncology